The economic group to which the Company currently belongs was founded in 1987 by its founding partners, Norival Bonamichi and Jardel Massari, initially focused exclusively on the manufacture of veterinary medicines and other products for production animals (cattle, horses, poultry, and swine).
From 1987 to 1999, operating growth occurred organically and largely within the production-animal segment. In 2000, Ourofino took its first step toward diversification by also entering the companion-animal market (dogs and cats).
From 2001 to 2004, believing that innovation and technological development are strategic differentiators, Ourofino invested in building a new, modern industrial and technology complex in Cravinhos, São Paulo, as the former facilities could no longer support the Company’s growth.
In 2007, the Company began investments to enter the biologics segment, with the construction of a modern industrial plant (factory and biosafe laboratory) for the production of foot-and-mouth disease vaccines. The construction was completed in October 2008, and certification by the Biosafety Committee of the Brazilian Ministry of Agriculture, Livestock and Food Supply (MAPA) was granted in December of the same year. This certification enabled Ourofino to receive virus seeds and begin vaccine development. The commercialization license was granted by MAPA in October 2010, after two years of development.
Also in 2007, Ourofino began construction of an industrial plant for hormonal therapeutic products, with the aim of developing a portfolio for complete Fixed-Time Artificial Insemination (FTAI) protocols. Construction of the factory was completed in early 2008, and commercialization of in-house production began in the second half of that year.
In 2014, after meeting various legal requirements, the Group completed its public offering process for the primary and secondary distribution of its common shares. The offering was carried out in the non-organized over-the-counter market, in accordance with CVM Instruction 400.
In 2015, we intensified our actions in foreign markets: (i) we strengthened our presence in Mexico by expanding the commercial team and increasing our customer base, and (ii) in September, we concluded the acquisition of our local distributor in Colombia, aiming to expand the Company’s presence in that country.
The years 2016 and 2017 were marked by major structural changes intended to restore the Company’s historical profitability levels, and the results have already begun to materialize.
The year 2018 represented a period of significant achievements and strengthening of the Company in the animal health market. The project to build the biologics plant made relevant progress with the start of production of the circovirus vaccine (PCV2b). In addition, the Company regained third place in market share, according to the SINDAN ranking.
In 2019, the Company began commercializing the circovirus vaccine (Safesui Circovírus). It also developed a strategic plan, reinforcing the vision of a broad, multi-species portfolio company with an incremental innovation strategy, focusing on a commercial approach centered on selling productivity in the field and intensifying the customer experience, and driving this strategy through improved execution.
In 2020, the Company looked simultaneously at its planning and at employees’ participation in execution. To contextualize the Company’s approach and engage its team to accelerate strategic results, the Company focused on evolving its organizational culture. The definition of the values “Play to Win,” “Care for People,” and “Connect with the World” encompasses the expected behaviors for the team to help the Company reach this new level of business, the objective of its strategy to reimagine Animal Health.
In 2021, aligned with its strategic plan and seeking to diversify the technological platforms of its products, the Company expanded its offering of recombinant vaccines with the launch of Safesui Mycoplasma. It also launched the Conclue line of rapid diagnostic test kits for eight diseases affecting dogs and cats, as well as the “Na Mosca” insecticidal ear tag and the Ourovac Rabies vaccine, which prevents rabies in herds.
In 2022, the Company delivered unprecedented solutions to customers, increased its participation in different markets, and launched a digital solutions ecosystem, including free and open training available to society at large. We also advanced the initiatives set out in our strategic plan, as well as indicators related to Environmental, Social, and Governance (ESG) topics.
In 2024, the Company changed its corporate name from “Ouro Fino Saúde Animal Participações S.A.” to “Ourofino S.A.”, as approved by the Extraordinary General Meeting held on July 17, 2024, along with the inclusion of additional activities in its bylaws. At the same meeting, the merger of Ouro Fino Agronegócio Ltda., the Company’s wholly owned subsidiary, was also approved, with its subsequent dissolution upon fulfillment of certain suspensive conditions on October 1, 2025.